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Abstract: Hepatitis C virus (HCV) represents a major health burden, with an estimated 180 
million chronically infected individuals worldwide. These patients are at increased risk of 
developing liver cirrhosis and hepatocellular carcinoma. Infection with HCV is the leading 
cause of liver transplantation in the Western world. Currently, the standard of care (SoC) 
consists of pegylated interferon alpha (pegIFN-α) and ribavirin (RBV). However this 
therapy has a limited efficacy and is associated with serious side effects. Therefore more 
tolerable, highly potent inhibitors of HCV replication are urgently needed. Both Specifically 
Targeted Antiviral Therapy for HCV (STAT-C) and inhibitors that are believed to interfere 
with the host-viral interaction are discussed.  
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1. Introduction 
HCV is a positive sense single-stranded RNA virus which belongs to the family of Flaviviridae, 
genus Hepacivirus. The 9.6 kb HCV genome encodes for a large polyprotein, that, following 
maturation results in at least 10 proteins: the structural proteins C, E1, E2 and p7 and the non-structural 
proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B [1]. HCV is a major cause of liver disease 
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worldwide. An estimated 3% of the world population is infected with HCV, with 3 to 4 million newly 
infected individuals each year [2]. About 20% of patients with chronic HCV will ultimately develop 
cirrhosis and are at increased risk to develop liver failure and/or hepatocellular carcinoma. There is no 
vaccine available and such vaccine is also not soon expected. The current standard of care (SoC) for 
HCV infection consists of a combined therapy of pegylated interferon alpha (pegIFN-α) and ribavirin 
(RBV) administered for 24 or 48 weeks depending on the HCV genotype. The response rate to SoC 
varies according to virus titre, patient characteristics and genotype, with genotype 1 being the most 
difficult to treat (sustained virological response (SVR) of 40-50%) [3]. Furthermore the SoC therapy is 
associated with side effects such as flu-like symptoms, fatigue, depression, cognitive dysfunction, 
which has a serious impact on compliance [4]. Newer forms of IFN are in (clinical) development, from 
which albinterferon is the most advanced. Albinterferon consists of a fusion between IFN-α-2b and 
human albumin and has a significantly longer half-life than pegIFN-α. The results from the first large 
trials indicate that albinterferon plus RBV had an efficacy comparable to that of the SoC [5]. 
Taribavirin, previously known as viramidine, is a prodrug of RBV that is preferentially taken up by the 
liver. Unlike RBV, taribavirin is poorly taken up by red blood cells. In clinical trials taribavirin, when 
combined with pegIFN-α, resulted in a significantly lower rate of anemia, however the efficacy was 
lower compared to RBV-containing SoC [6].  
Insights in the HCV life cycle and thus potential antiviral targets have long been hampered by the 
lack of efficient cell culture systems. However the generation of subgenomic HCV replicons, the HCV 
pseudoparticle model and more recently infectious HCV culture models were landmark developments 
that helped to the understanding of the life cycle of HCV and drug development [7]. 
2. Small Molecule Inhibitors of HCV Replication in Development 
2.1. Virus-Specific Strategies 
In theory, it should be possible to design selective inhibitors of every step in the replication cycle of 
HCV. The NS3/NS4A protease and the NS5B RNA-dependent RNA polymerase (RdRp) so far 
emerged as the most successful antiviral targets. Several inhibitors of the NS3 serine protease as well 
as nucleoside and non-nucleoside inhibitors of the NS5B polymerase are being or have been developed 
and some are currently in clinical trial. Inhibitors of other targets such as of the entry process, of the 
NS4A or NS4B protein and of the NS5A protein have only been recently identified.  
2.1.1. Entry Inhibitors 
Attachment of HCV virions to the cell surface followed by internalization is the first step in a 
cascade of interactions between virus and host cell that is required for infection. 
ITX4520, ITX5061  (iTherx Pharmaceuticals). The small-molecule inhibitor ITX4520 interacts 
with SR-BI, a hepatocyte factor involved in the docking and entry of the virus [8]. Another small 
molecule inhibitor that was initially characterized as a p38 MAPK inhibitor, ITX5061, exhibits 
picomolar antiviral potency in HCV genotype 1 and 2 and is currently being evaluated in phase IIa 
clinical trials [9,10].  
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Figure 1. New antivirals for the treatment of HCV and current stage of development. 
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Pro 206 (Progenics Pharmaceuticals). Pro 206 inhibits HCV entry at a post-attachment step and 
exhibits potent antiviral activity in the HCVpp model (EC50 = 2 nM) as well as in the HCVcc model 
(EC50 = 5.7 nM). Pro 206 and IFN-α-2a act in vitro (HCVcc) in an additive fashion. The development 
of Pro 206 has been stopped [11]. Second-generation lead compounds are in preclinical development 
[12].  
JTK-652 (Japan Tobacco). JTK-652 showed inhibitory activity against HCV genotype 1a and 1b 
pseudotyped viruses (in HepG2 cells and human primary hepatocytes). Multiple ascending doses of 
400 mg (n = 9) and 800 mg (n = 9) JTK-652 TID or placebo for 14 days were safe and well tolerated Viruses 2010, 2                              
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in 8/12 healthy male subjects. However, in genotype 1 infected patients, there were no significant 
changes in HCV RNA to baseline after 29 days of 100 mg JTK-652 TID. Further development of this 
compound was halted [13]. 
Cyanovirin-N. The lectin cyanovirin-N (CV-N) was originally identified as an inhibitor of HIV-1 
and HIV-2 replication [14], but exerts also in vitro anti-HCV activity. CV-N inhibits the infectivity of 
HCVpp and HCVcc at low nanomolar concentrations [15]. This antiviral effect results from an 
interaction of CV-N with N-linked glycans on the HCV envelope glycoproteins, thereby preventing the 
interaction of HCV glycoprotein E2 with the CD81-receptor. 
2.1.2. P7 Inhibitors 
The HCV p7 protein is a “viroporin” (virus encoded ion channel) that is critical for HCV virus 
infection. P7 is critical for the release of infectious virions in vitro and in vivo [16,17]. When its ion 
channel activity is blocked, virus production is significantly reduced [18]. The sensitivity of this 
channel to small-molecule inhibitors renders p7 a promising target for novel therapies. 
BIT225 (Biotron Limited). BIT225, N-[5-(1methyl-1H-pyrazol-4-yl)-napthalene-2-carbonyl]-
guanidine, was identified in a HCV p7 bacterial assay and was shown to be active in vitro against 
bovine viral diarrhoea (BVDV), a HCV related virus [19]. In a phase I study, safety and efficacy of 
two doses of BIT225 (35 and 200 mg, twice daily, 7 days) were examined in treatment-naïve or non-
responder patients. The mean change in viral load was modest (with a maximum of -0.5 log10) in the 
200 mg cohort [20].  
2.1.3. NS3 Protease Inhibitors  
The amino-terminal domain of the multifunctional HCV NS3 protein forms, together with NS4A, a 
heterodimeric serine protease that cleaves the downstream region of the HCV polyprotein into four 
functional non-structural proteins [21]. The carboxy-terminal domain exerts a helicase/NTPase activity 
that unwinds the viral RNA [22]. Despite the fact that the substrate-binding cleft of the protease is 
rather shallow and largely hydrophobic, making it, in theory, a difficult target, several potent inhibitors 
are now in preclinical and clinical development.  
Ciluprevir (BILN 2061) (Boehringer-Ingelheim). The macrocyclic peptidomimetic BILN 2061 
was the first HCV NS3/4A protease inhibitor to enter clinical trials [23]. When given to genotype 1 
HCV patients during 2 days BID in monotherapy, BILN 2061 resulted in a rapid, dose-dependent 
decline of the viral load of 2-3 log10 IU/ml [24]. In genotype 2 and 3 HCV patients the effect was 
however less pronounced, indicating that treatment response may also depend on HCV genotype [25]. 
Drug resistance was rapidly selected in vitro, with a single amino acid mutation (either R155Q, A156T 
or D168V) in the NS3 protease being sufficient to confer resistance [26]. Because of cardiotoxicity in 
animal models the development of Ciluprevir was stopped. 
Telaprevir/VX-950 (Vertex Pharmaceuticals). VX-950 is a potent peptidomimetic (α-ketoamide) 
inhibitor of the HCV serine protease that was discovered using structure-based drug design [27] and is 
one of the most extensively studied STAT-C drugs. In contrast to BILN 2061, which is a non-covalent 
reversible inhibitor, VX-950 forms a covalent but reversible complex with the NS3/4A serine protease 
and has slow binding and dissociation kinetics [28]. Viruses (replicons) carrying the dominant Viruses 2010, 2                              
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resistance mutation for VX-950 in vitro (A156S) remain sensitive to BILN 2061, reciprocally the 
major BILN 2061-resistant mutants (D168V/A) are fully susceptible to VX-950 [29]. The variants 
A156T/V confer resistance to both BILN 2061 and VX-950 [30]. During a phase Ib clinical study, 
HCV genotype 1 patients were treated for 14 days with VX-950 in monotherapy at a dosage of 450 mg 
or 750 mg every 8 hours or 1250 mg every 12 hours (or placebo). A maximal median viral load 
reduction of 4.4 log10 IU/ml was reached in the optimal-dose group (patients who received 750 mg 
every 8 h) [31]. However viral breakthrough, associated with a number of mutations that confer low-
level resistance (V36A/M, T54A, R155K/T, and A156S) and high-level resistance (A156V/T, 36 + 
155, 36 + 156) to telaprevir, was noted in a significant number of patients during the second week of 
treatment [32]. The rapid selection of resistance in monotherapy, underlines the need for a combination 
therapy. Telaprevir was accordingly studied in combination with pegIFN-α in a group of treatment-
naïve, genotype 1 HCV patients for 14 days. The effect on viral load was more pronounced with the 
combination therapy compared with either VX-950 or pegIFN-α monotherapy, with a mean decrease 
of 5.5 log10, 4.0 log10 and 1.0 log10 IU/ml respectively [33]. The safety of a triple therapy, in which 
VX-950 (750 mg every 8h) was combined with the SoC pegIFN-α-2a (180 µg/week) and RBV (1000 
or 1200 mg/day), was consecutively studied in 12 treatment-naïve genotype 1 HCV patients for 28 
days. All patients enrolled achieved undetectable HCV RNA levels by day 28. None of the patients 
experienced serious side effects [34]. These results warranted the set-up of 2 phase II clinical trials, 
named PROVE 1 and 2 studies, recruiting patients from the US and Europe, respectively. During the 
PROVE 1 study, treatment-naïve genotype 1 patients were randomized into 4 treatment groups, 
comprising standard therapy (pegIFN-α 180 µg/week and RBV 1000/1200 mg/day for 48 weeks); 
triple therapy i.e., telaprevir (750 mg every 8 h) added to this SoC for 12 weeks, followed by an 
additional treatment period of pegIFN-α and RBV for 0, 12 or 36 weeks. The rate of SVR was 
significantly higher in the groups that received triple therapy compared to those who received the SoC 
(control group), 35% - 67% respectively, compared to 41%. Triple therapy resulted in the highest rates 
of rapid virological response (RVR or plasma HCV RNA < 10 IU/ml at week 4), i.e., 81% versus 11% 
in the control group and low rates of relapse following cessation of treatment. Data were not 
substantially different between the groups receiving an additional standard therapy treatment for 12 or 
36 weeks after triple therapy, indicating that a total treatment duration of 24 weeks (instead of 48 
weeks) might be sufficient for the majority of patients [35]. The PROVE 2 study, conducted in Europe, 
had a similar study design as the PROVE 1 study, with as main difference that the group receiving 
triple therapy followed by standard therapy for 36 weeks, had now been replaced by a combination 
treatment of VX-950 and pegIFN-α (without RBV) for 12 weeks. The results from this study support 
the conclusions made for PROVE 1. The groups receiving triple therapy had greater SVR rates 
compared to the group receiving the SoC, i.e., 60%-69% versus 48% respectively. In the group, 
receiving 12 weeks SoC following triple therapy, there was also a trend towards a higher SVR rate and 
a lower relapse rate than in the group in which patients received only triple therapy, favouring the 
addition of a period of pegIFN-α and RBV consolidation. The group treated with telaprevir combined 
with pegIFN-α without RBV had a low SVR rate (36%) and a high relapse rate (48%), highlighting the 
importance of RBV co-administration in future regimens [36]. In both trials, adverse effects such as 
rash, pruritis and anaemia were more common in the VX-950 containing treatment groups than in the 
groups receiving the SoC alone. Accordingly the discontinuation rates were higher for these groups Viruses 2010, 2                              
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compared to the control group. In the PROVE 3 trial, the efficacy of VX-950, in genotype 1 HCV 
patients who failed prior treatment with the SoC, was evaluated. During this phase IIb study telaprevir 
was combined with pegIFN-α with or without RBV. The enrolled patients can be categorized into non-
responders, prior relapsers and prior breakthroughs to pegIFN and RBV treatment. The triple 
combination regimens (pegIFN/RBV/VX-950 for 12 or 24 weeks, followed by pegIFN/RBV for 12 
and 24 weeks) resulted in significantly higher SVR rates (51% and 53% respectively), compared to the 
SoC regimen (14%). In more detail, 38% of prior non-responders, 76% of prior relapsers and 63% of 
prior breakthrough patients achieved a SVR. The group treated with telaprevir in combination with 
IFN without RBV had a SVR rate of 24%, again confirming the importance of RBV [37]. During two 
phase IIa studies (named study C209 and C210) telaprevir (750 mg every 8 h) was administered alone 
or in combination with the SoC in treatment-naïve genotype 2, 3 (study C209) and 4 (study C210) 
patients for 15 days. In genotype 2 patients telaprevir monotherapy, the combination with the SoC or 
the SoC alone resulted in a mean maximal reduction in viral load of -4.0 ± 0.49, -5.5 ± 0.24 and  
-4.0 ± 0.70 log10 IU/ml, respectively; while in genotype 3 patients the same strategies resulted in a 
reduction of -0.80 ± 0.33, -4.7 ± 0.32 and -4.5 ± 0.36 log10 IU/ml, for genotype 4 the changes in viral 
load were -1.4 ± 0.30, -3.50 ± 0.48 and -2.0 ± 0.40 log10 IU/ml, respectively. Thus telaprevir proved 
highly potent against HCV genotype 2, while its activity against genotype 3 was rather limited [38]. 
Telaprevir in combination with the SoC had a greater activity against HCV genotype 4 than the SoC or 
telaprevir monotherapy alone [39]. Telaprevir is currently being tested in phase III clinical trials, 
named ADVANCE, ILLUMINATE (in treatment-naïve patients) and REALIZE (in treatment-
experienced patients). 
Boceprevir/SCH 503034 (Schering Plough/Merck). Boceprevir is another peptidomimetic (α-
ketoamide) reversible covalent inhibitor of the NS3/4A protease, which showed potent in vitro  
antiviral activity and additive potency when combined with pegIFN-α [40]. Three mutations T54A, 
V170A and A156S conferred low to moderate levels of resistance to boceprevir, while A156T 
conferred the highest level of resistance in vitro [41]. During a phase Ib study, safety parameters and 
virologic response of the combination of SCH 503034 and pegIFN-α-2b were assessed in HCV 
genotype 1 non-responders. Patients received boceprevir (200 or 400 mg every 8h) as a monotherapy 
for 7 days, pegIFN-α-2b as a monotherapy for 14 days and the combination of both compounds for 14 
days with “washout” periods between each treatment period. The combination treatment was well 
tolerated and resulted in an additive antiviral effect, with a mean maximal reduction in viral load of 
2.88 ± 0.22 log10 IU/ml (pegIFN-α + 400 mg SCH 503034), while boceprevir monotherapy (400 mg) 
resulted in a reduction of 1.61 ± 0.21 log10 IU/ml and pegIFN-α-2b monotherapy in a reduction of 1.26 
± 0.20 log10 IU/ml [42]. Genotypic resistance analysis, in patients who received boceprevir (400 mg 
BID or TID) alone for 2 weeks, identified mutations V36M/A, T54A/S, V55A, R155K/T, A156S and 
V170A in the NS3 protease [43]. HCV genotype 1 treatment-naïve patients were enrolled in the 
SPRINT-1 phase II study, to evaluate the most effective treatment strategy. A higher dosage of 
boceprevir (800 mg TID) was evaluated in combination with the SoC in 5 different treatment regimens 
(i.e., 4-week lead-in (or no lead-in) with SoC prior to the addition of boceprevir for an additional 24 or 
44 weeks; triple therapy for 48 weeks with lower dose RBV) and compared to the SoC without 
boceprevir. The rationale for this lead-in treatment period with the SoC is based on the fact that both 
pegIFN and RBV reach steady-state concentrations by week 4. Patients thus receive the protease Viruses 2010, 2                              
 
 
832
inhibitor first at a time when the backbone drug levels have been optimized, this may minimize the 
period of total treatment time required and may help reduce the likelihood for the development of 
resistance. SVR was significantly increased in the boceprevir arms compared to the SoC control arm. 
PegIFN and boceprevir combined with a low dose of RBV resulted in an increased viral breakthrough, 
relapse and lower efficacy, indicating the importance of RBV. Data suggest that a lead-in phase may 
be favoured in the patients treated for 48 weeks, but this needs to be further substantiated [44]. Only 
18% of patients, who first achieved undetectable HCV-RNA after week 8, benefited from a longer 
treatment regimen of 48 weeks. Response-guided therapy based on week-8 viral response may thus 
offer a predictive tool to individualize therapy [45]. Safety data from the HCV SPRINT-1 study 
revealed that the most common adverse events reported in the boceprevir arms were fatigue, anemia, 
nausea and headache. The incidence of skin adverse events (rash or pruritis) observed in the boceprevir 
arms was comparable to that seen in the control arm. Boceprevir has also progressed to phase III 
clinical trials in which treatment-naïve (SPRINT-2) and prior non-responder (RESPOND-2) patients 
will receive a lead-in treatment with the SoC for 4 weeks prior to the addition of boceprevir.  
TMC435350 (Tibotec and Medivir AB). TMC435350 is a cyclopentane-containing NS3/4A 
protease inhibitor with potent in v itro anti-HCV activity and a high selectivity index (5.875), as 
demonstrated in a subgenomic 1b replicon system. The compound exerts synergistic activity in 
combination with IFN-α and a NS5B inhibitor, and additive activity when used in combination with 
RBV in vitro. It has a good tissue distribution and bioavailability [46]. Once daily TMC435350 given 
orally during a phase I study, was generally safe and well tolerated and demonstrated potent antiviral 
activity (median maximal reduction of 3.9 log10 IU/ml in viral load when given to patients at 200 mg 
once daily for 5 days) [47]. Currently TMC435350 is evaluated in a phase II clinical trial (OPERA 1), 
in which treatment-naïve and treatment-experienced HCV genotype 1 patients receive TMC435350 
(25 mg daily, 75 mg daily, 200 mg daily, and 400 mg daily) or placebo with or without the SoC for 4 
weeks, followed by SoC treatment until week 48 (or optionally, until week 24 for patients with an 
undetectable HCV viral load at week 4). Interim analysis of the cohort in which non-responders or 
relapsers to SoC received triple therapy with once daily TMC435350 (75-200 mg) or placebo for 4 
weeks, revealed that triple therapy was well tolerated and resulted in potent antiviral activity with 
mean decreases in viral load of 4.3 – 5.3 log10 IU/ml, compared to 1.5 log10 IU/ml in the placebo 
group. The most common adverse effect was an influenza-like illness. Mild to moderate increases in 
bilirubin were observed in the highest doses group [48].  
ITMN-191/R-7227 (Intermune and Roche Pharmaceuticals). ITMN-191 has potent in vitro anti-
HCV activity against NS3/4a proteases derived from genotypes 1-6. The combination of ITMN-191 
with pegIFN resulted in vitro in a synergistic antiviral effect [49]. Furthermore the combination of 
ITMN-191 with the active moiety of either R1626 or R7128, which are both nucleoside analogue 
inhibitors of the HCV polymerase, resulted in enhanced antiviral activity and suppression of ITMN-
191 resistant variants [50]. During a phase Ib study, genotype 1 treatment-naïve or prior non-responder 
HCV patients, were treated for 14 days with ITMN-191 BID or TID (total daily dose of up to 600 mg). 
ITMN-191 reduced HCV RNA in a dose-dependent manner with a maximal median decrease in HCV 
RNA of -3.8 log10 IU/ml in treatment-naïve and -2.5 log10 IU/ml in prior non-responder patients. No 
severe side effects were observed [51]. Viral variants (R155K) with reduced drug sensitivity were 
detected in a subset of patients that experienced a virologic rebound. When ITMN-191 (ascending Viruses 2010, 2                              
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doses ranging from 100 mg to 600 mg) was administered to treatment-naïve HCV genotype 1 patients 
in combination with the SoC for 14 days, this resulted in a pronounced decline in viral load of -4.7 to  
-5.7 log10 IU/ml, compared to -2.0 log10 IU/ml for the SoC. Combination therapy appeared generally 
safe and well tolerated [52]. 
MK-7009/Vaniprevir (Merck). The macrocyclic non-covalent NS3-4A protease inhibitor MK-7009 
proved to be a potent inhibitor (EC50-values in the nanomolar range) of in vitro anti-HCV replication. 
MK-7009 had reduced activity on the replication of replicons that carried the following mutations 
Q41R and F43S (3-5 fold), for R155K, A156T and D168Y (125-270 fold) [53]. During a phase IIa 
study HCV genotype 1 treatment-naïve patients received MK-7009 (ascending doses of either 300 mg 
BID, 600 mg BID, 600 mg QD, or 800 mg QD) or placebo in combination with pegIFN and RBV for 
28 days. All patients continued pegIFN/RBV treatment for an additional 44 weeks. After 28 days of 
therapy, 69 to 82% of patients in the regimens containing MK-7009 versus 6% in the placebo group 
achieved undetectable HCV RNA levels. Interim results at week 12 indicated high rates of viral 
suppression to undetectable levels in patients treated with MK-7009 in combination with SoC for the 
initial 28 days (77-89% versus 60% in control (placebo) group). Resistant HCV variants at positions 
155 and 168 were detected in viral breakthrough patients. No serious adverse events were observed 
during this study [54]. A phase IIb study has been initiated to evaluate the safety, tolerability and 
efficacy of MK-7009 when administered concomitantly with pegIFN/RBV to treatment-experienced 
patients with chronic HCV genotype 1. 
BI 201335 (Boehringer-Ingelheim). BI 201335 is a potent peptidomimetic HCV protease inhibitor. 
Ascending doses of BI 201335 were given to HCV genotype 1 treatment-naïve patients as a 
monotherpay for 14 days, followed by triple combination therapy with the SoC for an additional 14 
days. BI 201335 monotherapy induced a pronounced virologic response with a median maximal 
reduction in viral load of -4.2 log10 IU/ml in the highest dose group (240 mg). However, a majority of 
patients in all dose groups experienced viral rebound during monotherapy. At higher doses an 
increased incidence of headache, gastrointestinal symptoms and unconjugated hyperbilirubinaemia 
was observed [55]. During a second study HCV genotype 1 treatment-experienced patients received 
ascending doses of BI 201335 (48 mg, 120 mg and 240 mg) in combination with the SoC for 28 days. 
In the highest dose group the median maximal reduction in viral load was -5.3 log10 IU/ml, also no 
viral breakthroughs were seen in this group, while this was observerd in 33% and 14% of patients in 
the 48 mg and 120 mg groups, respectively [56]. The predominant mutations in on-treatment viral 
rebound samples were R155K and D168V [57]. Safety and efficacy of BI 201335 was also assessed 
during a phase Ib trial, in which genotype 1 patients with compensated liver cirrhosis and non-response 
to previous SoC, were treated with 240 mg, once or twice daily, in combination with SoC for 28 days. 
All patients received a single loading dose of 480 mg of BI 201335 as the first dose. All patients 
showed a rapid and continuous decline in viral load with a mean reduction of -4.9 and -5.0 log10 IU/ml 
on day 28 in the 240 mg, once and twice dosing a day, respectively. No breakthrough was observed 
during treatment [58].  
Narlaprevir/SCH 900518  (Schering Plough/Merck). SCH 900518 has potent in vitro  antiviral 
activity in the replicon system with EC50-values in the nanomolar range. The safety and antiviral 
activity were evaluated in a clinical study in which treatment-naïve and -experienced HCV genotype 1 
patients received SCH 900518 for 7 days in monotherapy (at 800 mg TID or 400 mg BID + ritonavir). Viruses 2010, 2                              
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After a 4 week washout period the compound was administered together with pegIFN for 14 days, 
additionally patients received the SoC for 24 or 48 weeks. This treatment regimen resulted in a SVR in 
81% and 38% of treatment-naïve and treatment-experienced patients, respectively. In a number of 
SCH 900518 dosed patients the variations R155K, A156T/S, V36M/L were detected [59 ,60]. During a 
phase IIa study (NEXT-1) treatment-naïve genotype 1 patients receive SCH 900518 (200 mg or   
400 mg once daily) with ritonavir (100 mg daily) with the SoC for 12 weeks, with or without a 4 week 
lead-in period with the SoC, additionally they will be treated with 12 or 36 weeks of SoC. Interim 
results revealed that all treatment strategies resulted in a pronounced drop of HCV, with >85% RVR in 
the lead-in containing regimens [61]. 
2.1.4. NS3 Helicase Inhibitors 
The HCV helicase is believed to be essential for viral replication and forms a new attractive target 
for antiviral therapy. A few helicase inhibitors are in preclinical development; however none of them 
already passed to the clinical phase. Examples of molecules with reported anti-helicase activity are: 
benzimidazoles and benzotriazoles [62], the nucleotide-mimicking inhibitor QU663 [63], tropolone 
derivatives [64], an analogue of AICAR [65], acridone derivatives [66], a NS3 peptide [67], 
triphenylmethane derivatives [68], etc. 
2.1.5. Presumed Inhibitors of NS3/NS4A Interaction  
NS4A is an essential cofactor to the NS3 protease that facilitates the membrane anchoring of the 
NS3-NS4A complex to the endoplasmatic reticulum (ER) and enables efficient polyprotein processing 
[69]. The interaction between NS3 and NS4A may be a good target for developing HCV inhibitors.  
ACH-806, ACH-1095 (Achillion Pharmaceuticals). ACH-806/GS9132 is an acylthiourea 
compound that binds selectively to NS4A, thereby preventing the formation of functional replication 
complexes. The reduced function of replication complexes in the presence of ACH-806 is not due to 
inhibition of NS5B polymerase nor NS3 serine protease. ACH-806 can thus be seen as an alternative 
protease inhibitor with a mechanism different of that of classical NS3/NS4A protease inhibitors. This 
unique mechanism may contribute to the lack of cross-resistance between ACH-806 and other 
NS3/NS4A protease inhibitors as was shown in v itro [70]. ACH-806 resistant replicons carry 
mutations (C16S and A39V) in the N-terminal region of NS3 which are in a region that interacts with 
NS4A. Intriguingly, no resistance mutations were observed in NS4A [71]. In a phase Ib trial in HCV 
genotype 1-infected individuals significant reductions in HCV viral load were observed (300 mg, BID; 
mean change in HCV RNA at day 5: -0.91 log10 copies/ml vs. +0.05 log10 for placebo) [72]. The 
development of ACH-806 was discontinued because of adverse effects. ACH-1095/GS9525 is the lead 
compound of the second generation of NS4A antagonists and has a similar mechanism of action. 
ACH-1095 has completed preclinical studies.  
2.1.6. Inhibitors of NS4B-HCV RNA Binding 
HCV replication appears to be associated with intracellular membrane structures, the membranous 
web. This structure is believed to be induced by the NS4B protein. NS4B is also required to assemble Viruses 2010, 2                              
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the other viral non-structural proteins within the apparent sites of RNA replication. NS4B and HCV 
RNA have been shown to co-localize to the membranous web, suggesting that NS4B is in intimate 
contact with viral RNA in the context of authentic viral RNA replication [73]. Binding of the non-
structural protein NS4B to the 3'-terminus of the HCV negative RNA strand is a recently identified 
target for drug intervention. 
Clemizole (Eiger Biopharmaceuticals). Clemizole hydrochloride, a first generation antihistamine, 
was found to have a substantial inhibitory effect on HCV RNA replication mediated by its suppression 
of NS4B’s RNA binding (EC50 for viral replication is ~8 µM). Clemizole resistant variants carry 
mutations at position W55 and R214 in the NS4B protein [74]. A phase I proof-of-concept study, 
evaluating the safety and efficacy of clemizole as a single agent therapy in treatment-naïve patients 
infected with HCV genotypes 1 and 2, is underway. 
2.1.7. NS5A Inhibitors 
The non-structural 5A (NS5A) protein has no intrinsic enzymatic activity, but likely exerts its 
functions through interactions with viral and cellular factors. It is a pleiotropic protein which plays an 
essential role in the HCV viral life cycle both by affecting the viral RNA replication as well as by 
modulating the physiology of the host cell to favor viral replication [75,76]. It occurs in a basally and 
hyperphosphorylated form, with different putative functions during HCV replication [77]. Furthermore 
NS5A, and more particularly the C-terminal domain III, would be the key factor for the assembly of 
infectious HCV particles [78]. NS5A consists of three domains, from which the structure of domain I 
has been resolved [79]. NS5A has become a promising new therapeutic target for the treatment of 
HCV. 
A-831 and A-689 (Arrow Therapeutics and AstraZeneca).  A-831 (AZD2836) and A-689 
(AZD7295), from which the structures have not yet been disclosed, have potent in vitro anti-HCV 
activity in the replicon system and good pharmacokinetic properties. A-831 and A-689 have different 
chemical structures and bind to different sites of the NS5A protein. Both compounds are in phase I 
clinical development [80]. Furthermore Arrow Therapeutics reported on a new class of compounds 
targeting the NS5A protein with improved potency. This series of compounds specifically reduced the 
hyperphosphorylated form of NS5A and induced NS5A redistribution in the cytoplasm [81]. The lead 
compound had nanomolar activity against different HCV genotype replicons, acted synergistically 
when combined with other direct HCV antivirals (STAT-C) or IFN-α and increased the genetic barrier 
of resistance when combined with other HCV inhibitors (against NS3 and NS5B). Several mutations 
located in domain I of NS5A conferred resistance to this lead compound. These replicon variants 
remained however sensitive to other checmically distinct (NS5A-targeting) compound series and were 
less fit than wild type replicon [82].  
BMS-790052 (Bristol-Meyers Squibb). BMS-790052 is a potent and specific HCV NS5A inhibitor, 
which demonstrated broad genotype activity in vitro with EC50-values ranging from the pM to the low 
nM range. It exhibited an additive to synergistic in vitro  antiviral effect when combined with IFN-α 
and other small molecule HCV inhibitors. The compound most likely acts on the N-terminus of NS5A 
since drug resistance mutations mapped in this region [83,84]. The safety and efficacy of BMS-790052 
was evaluated in a randomized, double-blind, placebo-controlled, single ascending dose (1, 10, Viruses 2010, 2                              
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100 mg) study in HCV genotype 1 infected patients. All doses were well tolerated and had a safety 
profile similar to that of placebo. A mean maximal decrease in viral load of 1.8 log10 IU/ml and  
3.3 log10 IU/ml after 24 h was achieved in patients, who received a 1 mg or 100 mg single oral dose, 
respectively [85]. BMS-790052 is currently being evaluated in phase II clinical trials. 
2.1.8. NS5B (RNA-Dependent RNA Polymerase) Inhibitors 
The HCV NS5B protein is a RNA-dependent RNA polymerase (RdRp), which catalyzes the 
synthesis of a complementary minus-strand RNA, using the genome as a template, and the subsequent 
synthesis of genomic plus-strand RNA from this minus-strand RNA template. The HCV polymerase 
has the typical polymerase structure which is frequently compared with a right hand, where the palm 
domain contains the active site of the enzyme and where the fingers and the thumb are responsible for 
the interaction with the RNA. The fingertips are two loops that extend from the finger domain and that 
make contact with the thumb domain [86]. The HCV polymerase has been shown to be an excellent 
target for inhibition of HCV replication. Both nucleoside polymerase inhibitors and non-nucleoside 
polymerase inhibitors have been developed and several are or have been in clinical development.  
a. Nucleoside polymerase inhibitors 
Nucleoside analogues mimic natural polymerase substrates, causing chain termination and/or an 
increased error frequency when they are incorporated in a growing RNA chain. Generally, they show 
similar efficacy against all HCV genotypes, since the active site is well conserved among the distinct 
genotypes. All active site inhibitors of the HCV NS5B polymerase are ribonucleoside analogs.  
Valopicitabine (NM283) (Idenix Pharmaceuticals). Valopicitabine (NM283) is an oral prodrug of 
2’-C-methylcytidine (NM107) [87]. 2’-C-methylcytidine was initially identified as a replication 
inhibitor of the bovine viral diarrhea virus (BVDV) and was later shown to inhibit HCV replication. 
Replicons resistant to 2’-C-methylcytidine carry the S282T mutation in the viral polymerase and show 
a reduced fitness compared with the wild-type replicon [88]. In clinical trials, valopicitabine was 
combined with pegIFN-α. After 48 weeks of treatment, the difference in decline of HCV RNA 
between the combination of pegIFN and valopicitabine and the combination of pegIFN and RBV was 
not significant [90]. Based on the overall risk-benefit profile observed in clinical trials, development of 
valopicitabine was stopped.  
R1626 (Roche and Pharmasset). R1626 is a prodrug of the nucleoside analogue 4’-azidocytidine 
(R1479) [91]. Replicons resistant to R1479 contain the S96T mutation or the combination of S96T and 
N142T in the viral polymerase. Interestingly, R1479 is not cross-resistant with valopicitabine [92]. The 
combination of R1626 with pegIFN or with pegIFN plus RBV was evaluated in a phase IIa clinical 
trial in patients infected with HCV genotype 1. A high rate of HCV infection relapse on combination 
therapy was observed [94]. Furthermore, 78% of patients treated with 3000 mg twice daily and 45% of 
patients treated with 1500 mg twice daily developed grade 4 neutropenia [95]. Because of fatal drug-
induced lymphopenia, the development of R1626 was stopped at the end of 2008.  
R7128 (Roche and Pharmasset). R7128 is a diisobutyrate prodrug of PSI-6130, a cytidine 
nucleoside analogue (β-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine) [96]. Replicons resistant to PSI-
6130 contain the S282T mutation. However, this mutation results in a moderate three- to six-fold loss Viruses 2010, 2                              
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of sensitivity to PSI-6130. Thus, PSI-6130 presents a high barrier to resistance selection in vitro, 
selects for variants exhibiting only low-level resistance, and lacks cross-resistance with R1479 [97]. 
R7128 has shown antiviral efficacy in patients chronically infected with HCV genotype 1a and 1b 
(mean 2.7 log10 decline and maximum 4.2 log10 decline following 14 days of monotherapy of 1500 mg 
BID) [98]. Results of a phase I study of R7128 (500/1500 mg twice daily) in combination with pegIFN 
and RBV for 28 days demonstrated a significant antiviral effect (mean reduction in HCV RNA:   
5.1 log10 IU/mL for 1500 mg R7128, 3.8 log10 for 500 mg, and 2.9 log10 for placebo) [99]. When HCV 
genotype 2 and 3 prior non-responders were treated with R7128 (1500 mg twice a day) in combination 
with pegIFN and RBV for 28 days, a mean viral load reduction of 5.0 log10 was observed and R7128 
was generally well tolerated [100].  
b. Nucleotide analogues 
Nucleotide polymerase inhibitors are liver targeted prodrugs designed to enhance formation of its 
active triphosphate in the liver while minimizing systemic exposure of the nucleotide drug and its 
nucleoside metabolite. IDX-184  (Idenix Pharmaceuticals), a liver-targeted prodrug of   
2'-methylguanosine monophosphate, demonstrated multilog viral load reductions in HCV-infected 
chimpanzees receiving 10 mg/kg for 4 days (mean HCV RNA decline: 1.4 to 3.8 log10 copies/ml) and 
appeared to be safe and well tolerated in healthy subjects at single doses up to 100 mg [101]. In 
treatment-naïve genotype 1 infected patients receiving 25, 50, 75 and 100 mg of IDX-184 once daily 
for three days and monitored for 14 additional days, the mean change in HCV RNA at the end of 
treatment was quite modest (-0.74 log10 for the 100 mg group) [102]. PSI-7851 (Pharmasset) is a 
prodrug of a uridine nucleotide analog PSI-6206 monophosphate. PSI-7851 demonstrated 
approximately 15- to 20-fold greater in vitro potency (EC90 = 0.31 μM) than PSI-6130 in a replicon 
assay [103]. Multiple oral doses of PSI-7851 (50 mg, 100 mg and 200 mg once daily for 3 days) were 
evaluated in 30 treatment-naïve HCV-infected patients. HCV RNA in the PSI-7851 treatment groups 
declined in a dose dependent manner after 3 days of monotherapy with mean reductions of -0.49, -0.61 
and -1.01 log10 IU/mL for 50, 100 and 200 mg QD, respectively [104]. 
c. Non-nucleoside polymerase inhibitors 
Non-nucleoside polymerase inhibitors are allosteric inhibitors that bind to less conserved sites 
outside the active site and inhibit the catalytic efficiency of the enzyme’s active site machinery by 
preventing a conformational transition needed for the initiation of RNA synthesis. Since the 
mechanism of action of non-nucleoside inhibitors differs from that of nucleoside inhibitors, cross-
resistance between these two classes is unlikely to occur. A number of structurally unrelated series of 
non-nucleoside inhibitors have been reported; these include, but are not limited to, benzimidazoles, 
benzothiadiazines, thiophene derivates and benzofuranes. At least 4 different sites (A-D) have been 
shown to be targeted by non-nucleoside inhibitors; sites A and B are located in the thumb domain, sites 
C and D are located in the palm domain. In contrast to nucleoside inhibitors, a restricted spectrum of 
activity of non-nucleoside inhibitors against different HCV genotypes has been observed.  Viruses 2010, 2                              
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Figure 2. Binding sites for HCV polymerase inhibitors.  This figure is created using 
Chimera [105] based on superposition of different pdb structures using the Dali server 
[106]. The superimposed structures are 1GX6 (active site with UTP), 2BRK (with 
benzimidazole in thumb domain site 1), 1OS5 (with dihydropyranone in thumb domain 2 
site), 1YVF (with benzothiadiazine in palm domain site 1), 3FQL (with benzofuran in the 
palm domain site 2). The palm, fingers and thumb domains are colored blue, yellow and 
red respectively. UTP and benzofuran have yellow carbons, the other molecules green 
carbons. Mn++ ions in the active site are grey. Mutations in different regions have a 
different color: salmon for residues P495, P496, V499 in thumb domain 1, magenta for 
L419, M423, I482 in thumb domain 2, gold for N411, M414 in palm domain 1, cyan for 
C316, S365 in palm domain 2, green for C445, Y448, Y452 in the beta-hairpin loop. 
 
 
Thumb domain 1 (site A) 
The first non-nucleoside polymerase inhibitor that entered clinical trials was JTK-003. This 
benzimidazole compound is non-competitive with nucleotide incorporation and is believed to interact 
with an allosteric site on the surface of the thumb domain; drug resistant variants carry mutations at 
position P495 [107]. Inhibition of the viral polymerase results from the formation of intramolecular 
contacts between the thumb and the finger domain thus forcing the enzyme into an ‘open’, inactive 
conformation. JTK-003 was found to be well tolerated in phase I dose-ranging studies. The clinical 
development was however discontinued for unknown reasons. 
Another class of non-nucleoside inhibitors that bind to RdRp site A, are indole-based inhibitors 
such as MK-3281 and BILB-1941 (Merck, Boehringer Ingelheim). In preclinical studies, MK-3281 
proved equipotent against HCV genotype 1a, 1b and 3a, but weak activity against genotypes 2a and 2b Viruses 2010, 2                              
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[108]. MK-3281 as monotherapy (800 mg MK-3281 BID for 7 days) was well tolerated and 
demonstrated strong antiviral activity against genotype 1b HCV with no evidence of viral 
breakthrough. Activity against genotype 1a and genotype 3 was however limited (mean maximum 
reductions from baseline of HCV viral RNA: 1.3 (0.15), 3.8 (0.19), and 1.2 (0.16) log10 IU/mL for 
genotype 1a/1b/3, respectively) [109]. Although BILB-1941 demonstrated reasonable activity in 
patients infected with HCV genotype 1 (viral load decreased by > or = 1 log10 IU/ml in 2/8, 2/8, 1/8, 
2/7, 0/8, 2/8 and 4/5 patients on 60, 80, 100, 150, 200, 300 and 450 mg, respectively), the clinical 
development of this inhibitor was halted due to severe gastrointestinal intolerance [110]. 
Thumb domain 2 (site B)  
Thiophene carboxylic acid derivatives were reported to inhibit NS5B RdRp activity and HCV 
RNA replication in the replicon cell culture system [111]. Crystallographic studies revealed the 
existence of allosteric site B, a hydrophobic cavity located at the base of the thumb domain of NS5B 
[112]. Like site A inhibitors, thiophene carboxylic acid derivatives are non-competitive with 
nucleotide incorporation and inhibit an initiation step of RNA synthesis by interfering with 
conformational changes that are likely required for processive elongation of the replicating strand 
[113]. Thiophene-based inhibitors were found to select for Met
423 en Leu
419 resistant mutants in 
replicon cell culture experiment [114]. In 2006, a phase I proof-of-concept study was initiated with 
VCH-759 (Vertex). The drug was generally well tolerated and resulted in a significant reduction in 
viral load in treatment-naïve genotype 1 infected patients (> 1 log10 with a mean maximal decrease of 
1.9, 2.3 and 2.5 log10 after dosing for 10 days at 400 mg TID, 800 mg BID and 800 mg TID) [115]. 
However, on-treatment rebound of viremia was observed, which suggested the rapid emergence of 
resistant strains. Indeed, genotypic analysis of NS5B variants of VCH-759 treated patients revealed 
mutations at positions 423 and 419 [116]. A second, more potent thiophene-based compound, VCH-
916 (Vertex), has recently completed a phase I trial to assess the safety and efficacy [117]. 
Administration to healthy volunteers of doses between 50 and 600 mg did not result in any serious 
adverse effects. In genotype 1 HCV infected patients, VCH-916 achieved a mean maximal decline in 
HCV RNA of 1.5 log10 at doses of 200 mg TID and 300 and 400 mg BID over 3 days of monotherapy. 
Further development of this polymerase inhibitor in combination with other anti-HCV agents is being 
pursued [118].  
In addition to thiophene-derived carboxylic acids, two other classes of molecules have been 
identified to target this allosteric site. Pyranoindole derivatives (Viropharma/Wyeth) (i.e., HCV-371 
and a follow-up compound HCV-086)  entered clinical development but  failed to demonstrate 
significant efficacy and development was therefore discontinued [119,120]. 
Another class of non-nucleoside polymerase inhibitors that interacts with site B is the class of the 
dihydropyranone derivatives [121]. PF-868554/Filibuvir  (Pfizer) is a potent and selective HCV 
inhibitor in vitro. The predominant resistance mutation in resistant replicons is M423T [122]. A phase 
I clinical trial initiated with PF-868554  in 2006, revealed that the safety profile of this inhibitor 
(50/100/300 mg BID or 300 mg TID for 14 days) was similar to that observed in placebo. As 
monotherapy (100–450 mg BID or 300 mg TID for 8 days), PF-868554 demonstrated dose-dependent 
inhibition of viral replication, with mean maximum reductions in HCV RNA ranging from −0.97 to Viruses 2010, 2                              
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−2.13 log10 IU/mL [123]. In treatment-naïve genotype 1 infected patients triple therapy [PF-868554 
(200, 300 or 500 mg BID) or placebo in combination with pegIFN (180 µg/wk) and RBV (1000/1200 
mg/day) for 4 weeks] was associated with a mean reduction (log10 IU/mL) in HCV RNA of −2.10, 
−4.46, −4.67 and −3.62 at day 28 for placebo, 200, 300 and 500 mg BID respectively [124]. 
Palm domain 1 (site C)  
Palm domain 1 is located at the junction of the palm and the thumb domains of NS5B and is in 
relatively close proximity to the catalytic site. The first class of palm domain 1 inhibitors was 
originally discovered by GlaxoSmithKline and is characterized by a benzothiadiazine scaffold. Akin to 
the thumb domain targeting compounds, benzothiadiazine-based compounds inhibit RNA synthesis 
before formation of an elongation complex [125]. In vitro benzothiadiazines select for Met
414 resistant 
mutants [126]. ABT-333 (Abbott Laboratories) is another benzothiadiazine inhibitor that is currently 
in phase I clinical trials. In genotype 1 infected, treatment-naïve patients, treatment with ABT-333 + 
pegIFN/RBV resulted in significantly greater decreases in HCV RNA versus placebo + pegIFN/RBV 
(ABT-333 300 mg BID, 600 mg BID, 1200 mg QD, or placebo for 28 days (2 days monotherapy plus 
26 days with pegIFN 180 μg/week + RBV 1000-1200 mg/d, weight-based)). The least square mean 
maximum HCV RNA change from baseline was -3.7, -4.0, and -3.5 log10 IU/mL for 300 mg BID, 600 
mg BID, and 1200 mg QD ABT-333+pegIFN/RBV, respectively, compared to -1.4 log10 IU/mL for 
placebo+pegIFN/RBV [127]. The activity of yet another analog A-837093, was studied in genotype 
1a/1b HCV-infected chimpanzees (30 mg/kg BID for 14 days). Maximum viral
 load reductions of 1.4 
and 2.5 log10 copies RNA/ml were observed
 for genotype 1a and 1b, respectively, within 2 days after 
the initiation of treatment, followed by rapid rebound due to the expected emergence of resistant virus 
variants [128]. Anadys Pharmaceuticals recently completed a phase Ib study with their 
benzothiadiazine-based inhibitor, ANA598, which was well tolerated in healthy volunteers. ANA598 
dosed 200 mg BID for 3 days as monotherapy resulted in antiviral activity, with median viral load 
decline of 2.4 log10 in treatment-naïve genotype 1 infected patients [129]. However, in a separate  
14-day study with healthy volunteers conducted to extend the safety and pharmacokinetic profile of 
ANA598, a severe rash was observed in some ANA598 treated subjects. Three patients (two in the  
800 mg once daily cohort and one in the 600 mg bid cohort) developed grade II rash and discontinued 
treatment after either six or seven days of consecutive dosing [130]. 
Another class of palm domain 1 binding compounds is the class of acylpyrrolidines 
(GlaxoSmithKline) [131]. GSK625433 was advanced into phase I clinical trials but this study was 
halted because of adverse effects noted in long-term mouse carcinogenicity studies. [132].  
Palm domain 2 (site D)  
Palm domain 2 partially overlaps with palm domain 1, in proximity to the enzyme active site and 
the junction between the palm and thumb domains. A class of benzofurans (Viropharma/Wyeth) was 
identified as potent inhibitors of in vitro HCV replication [133]. These molecules select for Leu
314, 
Cys
316, Ile
363, Ser
365 and Met
414 resistant mutants, which are almost all located in the allosteric palm 
domain 2 at the junction of the thumb and the palm domains of NS5B [134]. In phase I clinical trials, 
administration of 1000 mg BID HCV-796 for 14 days in genotype 1 infected patients resulted in a Viruses 2010, 2                              
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mean maximal reduction in viral load of 1.4 log10 after 4 days [135]. In a combination trial of HCV-
796 (doses ranging from 100 to 1000 mg BID) with pegIFN and RBV, mean viral load reductions at 
day 14 were 2.6-3.2 log10 for genotype 1 infected patients, increasing to 3.5-4.8 log10 in genotype non-
1 infected patients [136]. Because of safety concerns, the development of HCV-797 was halted.  
A class of imidazopyridines was identified as potent inhibitors of in vitro HCV replication [137]. 
Drug resistant variants carry mutations in the palm domain (C316Y) and inside the beta-hairpin of 
NS5B (C445F, Y448H, Y452H). This β-hairpin loop is located in close proximity to the catalytic 
active site and is believed to be involved in primer independent initiation of RNA replication. Within 
this class of imidazopyridines GS-9190 (Gilead) is currently being evaluated in phase II studies in 
combination with pegIFN and/or RBV. 
2.2. Host-Specific Strategies 
Cellular proteins that are essential for (efficient) HCV infection and replication may be targets for 
novel antiviral strategies. An advantage of HCV inhibitors that target host factors may be a higher 
genetic barrier than that of (most) inhibitors that target viral proteins. A disadvantage may be that side 
effects can be induced by inhibiting the primary roles of the host factors. We briefly discuss a selection 
of host factor-targeting inhibitors of HCV replication. 
2.2.1. Cyclophilin Binding Molecules 
Cyclophilins are abundant proteins that are present in every organ. They display peptidyl-prolyl cis-
trans isomerase activity which is important in de novo protein folding and isomerisation of native 
proteins [138]. There is a preponderance of evidence that cyclophilins play a crucial role in HCV 
replication. CypB has been proposed to be a functional regulator of the NS5B polymerase by 
enhancing its RNA binding activity [139]. Recently, CypA has been suggested as being the most 
indispensible cyclophilin for HCV replication [140-142]. Cyclosporine A (CsA), a widely used 
immunosuppressive drug, was shown to exert anti-HCV activity in vitro  [143,144]. CsA binds to 
cyclophilins and inhibits their cis-trans peptidyl-prolyl isomerase activity. The compound forms an 
inhibitory complex with cyclophilins that blocks the phosphatase activity of calcineurin in activated T-
cells. Tacrolimus (FK506), an immunosuppressive drug that interacts with calcineurin but not with 
cyclophilins, exerts no anti-HCV activity indicating that the immunosuppressive activity is not a 
prerequisite for potency against HCV [145]. A number of non-immunosuppressive cyclophilin binding 
compounds are currently in (clinical) development.  
Debio 025/Alisporivir (Debiopharm). Debio 025 is at least 10-fold more potent than CsA as a 
HCV-inhibitor, with an EC50-value in the nanomolar range (in the subgenomic replicon and infectious 
HCV system) [146]. The in vitro combination of Debio 025 with either SoC or STAT-C inhibitors 
[NS3 protease or NS5B (nucleoside and non-nucleoside) polymerase inhibitors] resulted in an additive 
antiviral activity. Debio 025 had the unique ability to clear hepatoma cells from their HCV replicon 
when used alone (at low concentrations) or in combination with IFN and/or STAT-C inhibitors. At 
concentrations that are readily achieved in human plasma (0.1 or 0.5 µM), Debio 025 was able to delay 
or prevent the development of resistance to HCV protease inhibitors as well as to nucleoside and non-
nucleoside polymerase inhibitors in vitro during a combined colony formation assay. In vitro selection Viruses 2010, 2                              
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of Debio 025 resistant replicon proved to be a very lengthy process. The compound remained active 
against replicons that were resistant to various NS3 protease- and NS5B polymerase inhibitors. 
Conversely, these STAT-C inhibitors retained wild type-activity in Debio 025 resistant replicon 
cultures [147]. Mutations identified in Debio 025 resistant replicons reside mainly in domain II of the 
NS5A gene (Con1 subgenomic replicon) [148] or near the cleavage site between NS5A and NS5B 
(JFH1 subgenomic repicon) [149].  
 In phase I clinical studies HCV/HIV-coinfected patients received Debio 025 in monotherapy (1200 
mg BID), a mean maximal decrease in viral load of 3.6 log10 IU/ml was observed after 15 days [150]. 
The efficacy and safety of Debio 025 was further evaluated in a phase II study in which HCV genotype 
1, 2, 3 and 4 treatment-naïve patients were randomized to receive escalating doses of Debio 025 (200, 
600, 1000 mg/day) combined with pegIFN-α-2a or monotherapy with either 1000 mg/day Debio 025 
or 180 µg/week pegIFN-α-2a for 4 weeks. In patients with genotype 1 and 4, the 600 mg- and 1000 mg 
- combination treatment resulted in a -4.61 ± 1.88 and -4.75 ± 2.19 log10 IU/ml decrease in viral load at 
week 4, respectively. Reduction in viral load in genotype 2 and 3 infected patients was more 
pronounced with reduction up to -5.91 ± 1.11 and -5.89 ± 0.43 log10 IU/ml, respectively, with the same 
treatment regimens [151]. The 200 and 600 mg dose were very well tolerated, whereas the 1000 mg 
dose was associated with isolated and reversible hyperbilirubinemia linked to inhibition of biliary 
canalicular transporters. However bilirubin levels returned to baseline after treatment cessation. 
Subsequently the effect of treatment with Debio 025 (400 mg or 800 mg) in combination with pegIFN-
α-2a and RBV was studied in HCV genotype 1 patients that were non-responders to the SoC. Debio 
025 at doses of 400 mg (with initial loading dose) and 800 mg daily for 29 days resulted in a 
significant decrease of HCV viral load of -1.96 - 2.38 log10 IU/ml, respectively, when combined with 
the SoC [152].  
NIM811 (Novartis). NIM811 is another oral non-immunosuppressive cyclophilin binding inhibitor, 
which exhibits also stronger in vitro anti-HCV activity than CsA. The combination of NIM811 with a 
protease inhibitor and (non)-nucleoside polymerase inhibitors resulted in an additive to synergistic 
effect, as tested in vitro. As is the case for Debio 025, it is much more difficult to develop resistance 
against NIM811 than against viral specific inhibitors. Furthermore no cross-resistance could be 
observed between these inhibitors, and NIM811 prevented, like Debio 025, the emergence of 
resistance development against STAT-C inhibitors [153]. When NIM811 at a dose of 600 mg B was 
given in combination with pegIFN-α-2a to genotype 1 HCV infected patients that previously failed on 
SoC, a mean drop in HCV RNA of -2.78 log10 IU/ml was observed after 14 days of treatment, 
compared to -0.58 log10 IU/ml decrease in the IFN monotherapy arm. The major safety concern was a 
decrease in platelets and an increase in serum bilirubin [154].  
SCY-635 (Scynexis). SCY-635 is also a non-immunosuppressive analogue of CsA that exerts potent 
anti-HCV activity in vitro. SCY-635 inhibited the peptidyl-prolyl cis-trans isomerase activity of CypA 
at nanomolar concentrations. The combination of SCY-635 with RBV or IFN-α-2b resulted in an 
additive to synergistic effect, as tested in vitro [155]. During a phase Ib clinical study HCV genotype 1 
patients were enrolled into one of three ascending cohorts (total daily dose: 300, 600, 900 mg) for 15 
days. No serious adverse events were observed. Consistent decreases in plasma RNA were observed 
only in the 900 mg cohort. Group mean and median nadir values were 2.20 and 1.82 log10 below 
baseline [156].  Viruses 2010, 2                              
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2.2.2. Glycosylation Inhibitors  
N-glycosylation of proteins is important for optimal folding and assembly into complexes. Proper 
folding and assembly of many viral glycoproteins is assisted by ER-resident chaperones [157]. Some 
chaperones interact with glycoproteins by binding to their N-glycan moieties. Before this interaction 
can take place, the N-glycans need to be modified by the trimming of two terminal glucose residues. 
This process is catalyzed by two ER-resident enzymes, α-glucosidases I and II [158]. In the lumen of 
the ER, HCV glycoproteins E1 and E2 are modified by N-linked glycosylation on well conserved sites 
among HCV genotypes [159]. Inhibition of the activity of ER-α-glucosidases results in 
misfolding/misassembly of the HCV glycoproteins and thereby leads to an accelerated degradation of 
E1-E2 heterodimers and a decrease in availability of these complexes for viral budding and 
morphogenesis. However, glucosidase inhibitors can cause side effects in vivo because of off-target 
inhibition of various glucosidases. Since HCV is particularly sensitive to ER-α-glucosidase inhibition 
compared with host proteins, glucosidase inhibitors should be specific for ER-α-glucosidases to avoid 
side-effects. 
Iminosugars. Iminosugar derivatives of the glucose analog deoxynojirimycin (DNJ) were identified 
as α-glucosidase inhibitors and exert broad antiviral activity including against HIV, influenza virus, 
flaviviruses, pestiviruses (BVDV), hepadnaviruses (HBV & WHV) and the hepatitis C virus (HCV) 
[160]. Inhibition of in vitro HCV replication by DNJ and analogues has been shown to be related to an 
effect on morphogenesis and a reduction of infectivity of virions that are residually released under 
treatment [18,161]. Recently, the anti-HCV activity of two alpha-1-C-alkyl-1-DNJ derivatives was 
reported. These molecules have different selectivity patterns towards gastro-intestinal oxidases 
compared to previously studied DNJ derivatives, but their anti-HCV activity was found to be slightly 
lower than the anti-HCV activity of the parental molecules, due to lower inhibition of ER-glucosidases 
[162]. 
Celgosivir (Migenix). Derivatives of the naturally occurring castanospermine, a well-known 
inhibitor of ER-α-glucosidase I, are reported to inhibit in vitro anti-BVDV activity [163]. The antiviral 
efficacy and safety of one of these derivatives, 6-O-butanoyl-castanospermine (Celgosivir/MX-3253), 
were demonstrated before in clinical trials in HIV-1-infected patients. Celgosivir used as monotherapy 
(200 mg once/twice daily, 400 mg once daily) was well tolerated in all dosage groups and resulted in a 
modest antiviral effect in treatment-naïve or IFN-intolerant genotype 1 HCV infected patients. Results 
of a phase II study in genotype 1 HCV-infected non-responder or partial responder patients showed 
that triple therapy of celgosivir (400 mg once daily), pegIFN and RBV produced a substantial decrease 
in viral load compared to current standard therapy (mean decrease of HCV RNA -1.63 log10IU/ml vs. -
0.92 log10IU/ml for SoC therapy) [164]. Clinical development of celgosivir is currently put on hold. 
2.2.3. Statins 
HCV requires elements of the cholesterol and fatty-acid biosynthetic pathways for efficient 
replication [165]. Lipoprotein receptors (LDL receptor, SR-BI receptor) have been reported to be 
involved in HCV entry [166]. Nevertheless, the role of the LDL-receptor in HCV entry is still 
uncertain. Cholesterol metabolism is also required for the assembly of VLDL particles. These Viruses 2010, 2                              
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lipoprotein particles have been shown to complex with HCV virions in serum [167]. Cholesterol- and 
sphingolipid-lowering compounds, like statins and myriocin, have been reported to inhibit HCV 
replication [168]. 
Statins. Statins, which are widely used for the treatment of hypercholesterolemia, inhibit 3-
hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in 
cholesterol biosynthesis in the liver. HMG-CoA reductase catalyzes the conversion of HMG-CoA to 
mevalonic acid [169]. Besides its cholesterol-lowering effect, statins were shown to inhibit the 
replication of subgenomic HCV-1b replicons and to suppress RNA replication of JFH-1 HCV 
[170,171]. In vitro combination studies of statins with IFN and selective HCV inhibitors (protease 
inhibitor VX-950, nucleoside polymerase inhibitor R1479, non-nucleoside inhibitors HCV-796 and 
GSK-4) resulted in an additive antiviral activity. Importantly, mevastatin delays or even prevents the 
development of HCV-796 escape mutants. Hence, the combination of selective HCV inhibitors with 
statins may also have the potential to delay or even to prevent resistance development in the clinical 
setting [172]. The precise mechanism of the anti-HCV activity of statins has not yet been unraveled. 
The anti-HCV activity of statins may possibly result from inhibition of geranylgeranylation of cellular 
proteins rather than the inhibition of cholesterol synthesis [173]. Geranylgeranylation is a post-
transcriptional modification that covalently attaches geranylgeranyl to various cellular proteins to 
facilitate their membrane association. These geranylgeranyl groups are isoprenoids synthesized in the 
cholesterol biosynthesis pathway. More recently, FBL2 has been reported to be a host target for 
geranylgeranylation. Geranylgeranylation of FBL2 appears to be critical for HCV replication because 
the association between FBL2 and NS5A, an interaction that is a prerequisite for HCV replication, 
depends on geranylgeranylation of FBL2 [174]. In vivo results of statin monotherapy have yielded 
conflicting results so far. Neither atorvastatin (after conventional 12-week therapy) nor rosuvastatin 
resulted in a reduction in viral load [175,176]. Nevertheless, fluvastatin was found to inhibit HCV 
RNA replication in HCV infected patients in a recently published study. The drug was well tolerated 
and resulted, at relatively low doses (20-80 mg daily), in a transient reduction in viral load (-0.5 to  
-1.75 log10, 2-5 weeks); higher doses of fluvastatin did not reduce viral load [177]. Also, a recent 
retrospective analysis demonstrated that statin use in combination with pegIFN and RBV was 
associated with a significantly higher SVR and viral response at week 4 and 12 [178]. A pilot study 
evaluating the combination of fluvastatin (20 mg daily) with pegIFN/RBV revealed that fluvastatin 
could be used safely to increase the response to pegIFN and RBV [179]. There is today obviously no 
compelling evidence that statins, used in monotherapy, may result in a marked reduction in HCV load 
in chronically infected patients. However, statins may have the potential to increase the efficacy of 
current or future HCV therapy. 
2.2.4. Nitazoxanide (Alinia®, Romark laboratories) 
Nitazoxanide (NTZ) is a thiazolide with activity against bacteria, protozoa and viruses. The 
antiviral activity of NTZ against HCV was discovered during its development for the treatment of 
cryptosporidiosis in patients with acquired immune deficiency syndrome (AIDS) coinfected with HCV 
[180]. NTZ and its primary metabolite, tizoxanide, inhibit HCV replication in vitro but do not induce 
antiviral resistance, since direct HCV viral resistance did not emerge with serial exposure to NTZ, Viruses 2010, 2                              
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suggesting that the genetic barrier of resistance to NTZ is high [181 ,182]. Although the mechanism of 
action is not known, it is assumed that the activity is related to (a) cellular rather than (a) viral target(s). 
NTZ has been reported to increase the phosphorylation of dsRNA-dependent protein kinase thereby 
resulting in the inducing of initiation factor 2 α which is an important factor in innate immune 
response.  
The antiviral effect of NTZ in HCV-infected patients was first reported in 2008 [183]. In genotype 
4 infected patients NTZ monotherapy (500 mg, BID) proved safe and resulted in a sustained 
virological response in 17.4% of patients. In another study, triple therapy with pegIFN, RBV and NTZ 
(180 µg pegIFN once weekly, 1000-1200 mg RBV/day, 500 mg NTZ, BID) for 36 weeks following a 
12-week lead-in with NTZ monotherapy (500 mg, BID) resulted in a SVR of 79% in treatment-naïve 
patients infected with HCV genotype 4, which was superior to the SVR rate achieved with the SoC 
using pegIFN and RBV for 48 weeks (SVR=50%) [184]. Currently two clinical trials are being 
performed, e.g. STEALTH-C2 and C3, in which the combined effect of NTZ (500 mg, twice daily) 
with RBV and pegIFN is studied in genotype 1 infected prior non-responders to pegIFN/RBV therapy 
or in genotype 1 treatment-naïve patients, respectively. Interim results of the ERAIS-C trial revealed 
that a regimen of NTZ (500 mg, BID), high dose RBV and pegIFN enhances rapid viral response 
(RVR) [185]. Another pilot study of lead-in NTZ enrolled cirrhotic patients with chronic HCV 
genotype 1 who failed previous therapies with pegIFN and RBV. These patients received NTZ 500 mg 
twice daily for 4 weeks followed by NTZ plus pegIFN 180 µg/week and weight based RBV for 48 
weeks. An interim analysis of this study indicates that treatment with lead-in NTZ in combination with 
pegIFN and RBV has demonstrated promising results in these difficult to treat patients [186].  
2.2.5. Silymarin Extracts 
Silymarin is a mixture of flavolignans extracted from the milk thistle (Silybum marianum). The 
main component is silibinin (a 50:50 mixture of silibinin A and silibinin B). Silibinin has strong anti-
oxidative and anti-fibrotic properties and has therefore been used for many years as a ‘hepatoprotector’ 
agent. Silibinin A and B, as well as Legalon SIL, a commercially available intravenous preparation of 
silibinin, exhibited an antiviral effect in the HCV replicon system [187]. Furthermore, these products, 
as well as a standardized silymarin extract (MK-001), inhibited infection of Huh 7 and Huh 7.5.1 cells 
by the JFH-1 HCV strain in a dose-dependent manner [188]. Recently silibin and related compounds 
were found to directly inhibit HCV NS5B polymerase [187]. In vivo results of silymarin extracts have 
yielded conflicting results so far. When Legalon SIL was administered intravenously for 7 days at  
20 mg/kg/day, HCV RNA was reduced by 3.02 ± 1.01 log10 in non-responder patients [189]. HCV 
RNA decreased further after 7 days of combined treatment of SIL with SOC (4.85 ± 0.85 log10). 
Beside mild gastrointestinal symptoms, IV silibinin therapy was well tolerated. However, when the 
antiviral effect of oral silymarin extracts was studied, no antiviral effect was found in HCV infected 
patients [190,191]. The discrepancies between previously mentioned studies are probably due to the 
dose and route of administration of the drug. Recently it was shown that high-dose administration of 
oral silymarin was associated with steady-state peak plasma concentrations of silibinin A and B 1 to 2 
orders of magnitude below the concentrations associated with antiviral effects in vitro. Moreover, Viruses 2010, 2                              
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trough concentrations were approximately 25-fold lower than peak concentrations, likely explaining 
the lack of antiviral effect of oral silymarin in vivo [191].  
3. Combination Therapy 
As HCV has a high replication rate without a proof-reading mechanism, the emergence of viral 
resistance forms a major issue within this class of specifically HCV-targeting molecules. To stand up 
to this problem combinations of molecules with different modes of action will play a key role in the 
future development of these compounds.  
Recently, various studies were performed to investigate the antiviral efficacy of combinations of 
HCV inhibitors in vitro. Selection of resistance of the combination of R1479 or PSI-6130 with a 
protease inhibitor or non-nucleoside inhibitor reduced the emergence of resistant colonies, suggesting a 
clear benefit of combination treatment [192]. When selecting replicons with dual resistance to 
inhibitors binding to the thumb and palm sites, combination experiments showed that dual-resistant 
replicons had amino acid substitutions that mapped directly to both the thumb and palm sites. Thus, 
combination therapy apparently did not significantly complicate the resistance profiles observed with 
single-compound treatments [114]. Combinations of inhibitors with a viral and a cellular target were 
also studied in vitro. The combined in vitro antiviral activity of Debio 025 and RBV or selective HCV 
inhibitors was shown to be additive and Debio 025 prevented resistance development against several 
STAT-C inhibitors [193]. Another HCV inhibitor with cellular target, mevastatin, delayed or even 
prevented the development of HCV-796 escape mutants [172]. 
The INFORM-1 trial is the first trial to study the combination of a nucleoside polymerase inhibitor 
(R7128) and a protease inhibitor (ITNM-191/R7227) in HCV infected patients. Both compounds 
inhibit different targets and are therefore good candidates for combination therapy. HCV genotype 1 
infected patients received up to 14 days oral combination therapy with escalating doses of either 500 or 
1000 mg BID R7128 & 100, 200 mg TID or 600 or 900 mg BID R7227, leading to a median HCV 
RNA change from baseline between -3.5 and -5.2 log10 IU/ml at day 14 [194]. Low dose combination 
therapy of R7128 with R7227 did not select for resistant mutants for up to two weeks of treatment 
[195]. 
4. Discussion 
Important progress in the development of potent and selective inhibitors of HCV replication has 
been made in the last decade. Several (relatively) well tolerated drugs are currently in clinical 
development and encouraging results have been obtained with some of these molecules. The ultimate 
goal is to develop a successful therapeutic strategy against most, if not all, HCV genotypes that results 
in a rapid and potent antiviral response and that does not, or only to a limited extent, allows the virus to 
develop drug-resistance. Such therapy would no longer require the use of ribavirin and interferon 
preparations, therapeutics that are associated with important side-effects. Drugs to be used in 
combination therapy must have non-overlapping resistance profiles. This is achievable, given the fact 
that inhibitors have been/are being developed that target (i) different steps in the viral life cycle 
(amongst which entry, the NS3 protease, the NS5B polymerase and NS5A) and (ii) cellular factors that 
are crucial for efficient viral replication (e.g., the non-immunosuppressive cyclophylin binding Viruses 2010, 2                              
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molecules). So far, inhibitors of the viral NS3 protease and NS5B polymerase as well as the viral 
NS5A (of which the precise function in the replication of the virus still remains to be unraveled) have 
been best studied and their value has been demonstrated in the clinical setting. Most polymerase 
inhibitors as well as the NS5A inhibitors have been discovered by (i) screening compound libraries in 
either target based assays (eg. RdRp assays) or in cell based assays (eg subgenomic replicons) 
followed by (ii) hit-to-lead optimization. NS3 protease inhibitors have basically been designed as 
peptidomimetics of the carboxyterminal domain of the cleavage site of the enzyme. It is somehow 
surprising that very few inhibitors of yet other targets, such as the NS4B, the NS3 helicase activity or 
the interaction between NS4A and the NS3 protease have not been identified. The reason, in particular 
for the viral helicase, may be that the molecules that are usually present in small molecule libraries 
have not the right scaffold (or may be too small) to exert activity against these targets.  
The viral polymerase has multiple targets for inhibition of viral replication. Besides the catalytic 
site, different allosteric sites exist that can each be targeted by specific inhibitors. In theory, a 
combination of two or three different NS5B RdRp inhibitors may thus suffice to design a combination 
therapy. In fact, Atripla, a HAART (highly active anti-retroviral therapy) consists of three inhibitors of 
the HIV reverse transcriptase, each with a different resistance profile. In vitro studies may help to 
develop combinations that are highly potent against HCV. Such combinations should also delay or 
prevent the development of resistant variants. Pharmaceutical companies that have two or more 
compounds in (clinical) development with non-overlapping resistance profiles may have the option to 
develop such combination therapies. Strategic partnerships of different companies that each owns one 
(or two) compounds that would be ideally combined with yet another inhibitor may possibly be needed 
to obtain the most powerful combination therapy. 
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